Michel Levesque, MD, Co-Founder and CEO
Michel Lévesque,MD, is the Founder and CEO, of Siragen Pharmaceuticals. A successful entrepreneur, neuroscientist and neurosurgeon, Dr Levesque is also an Associate Clinical Professor of Neurosurgery at the UCLA School of Medicine, member of the UCLA Brain Research Institute. He is the Chairman of the Foundation for Neural Repair, a not-for-profit foundation, sponsoring translational research to accelerate human trials . Dr. Lévesque has authored over 75 articles in peer-reviewed professional journals, contributed chapters to many leading neurosurgery treatises, has published over 200 scientific abstracts, and inventor of 7 patents. Dr. Lévesque received his medical degree at Universite de Montreal and completed post-graduate studies in neurosciences, studying central nervous system regeneration at Mc Gill University under Dr Albert Aguayo. He completed his neurosurgical training at the Montreal Neurological Institute and Mc Gill University, and a fellowship in functional neurosurgery.
Mohamedi Kagalwala, PhD, MBA, Co-Founder and Chief Scientific Officer
Mohamedi “Mo” Kagalwala, PhD, MBA, is the chief scientific officer at Siragen Pharmaceuticals. Dr. Kagalwala is responsible for overseeing the research and development activities including discovery and pre-clinical studies with all assets in the pipeline. He is regarded as one of the pioneers in the field of chromatin and epigenetics for his contributions to chromatin remodeling. Dr. Kagalwala trained at Bhaba Atomic Research Center, Trombay, India and National Center for Biological Sciences, Bangalore, India. Dr. Kagalwala was then offered a Research Associate position in neurobiology and neurodegenerative disorders at the Salk Institute in La Jolla, CA under Prof. Fred “Rusty” Gage. There he expanded his knowledge and expertise of neural stem cells to understand adult neurogenesis in the hippocampus and carried out biochemical and functional genomic analysis of iPSC derived Neural Stem Cells from Schizophrenia patients. There he laid the solid foundation for his research in the understanding the molecular mechanisms of aging and neurodegeneration.
Patricia Eastman, MHA ,Vice President Corporate Services
Patricia Eastman, MHA is Vice President Corporate Services at Siragen Pharmaceuticals. She has served as Senior Vice President for Corporate Affairs at Neurogeneration since 2008. She previously was CEO of Associated Students UCLA. Prior to this, she served as Vice President, Business Development, Cedars-Sinai Medical Center. She is a graduate of Arizona State University and Loma Linda University.
Scientific Advisory Board
Anthony Means, PhD, Baylor College of Medicine
Dr. Anthony R. Means is a pre-eminent biomedical scientist who studies how calcium participates in the regulation of cell function. He has been interested in the signaling pathways regulated by hormones and growth factors since graduate school where he worked on early actions of estrogen. Following postdoctoral training in Australia where he began investigations on the early actions of FSH in the male he continued this interest as a faculty member at Vanderbilt and Baylor College of Medicine. Close examination of immediate post-receptor signaling led to an appreciation of important roles for Ca2+ and the identification of a Ca2+ receptor that was subsequently christened calmodulin (CaM). Not only was Dr. Means one of the first to recognize the importance of CaM, he is the principle architect of a now central tenant in biology that CaM serves as the primary and ubiquitous receptor for calcium. He was the first to sequence the calmodulin protein, isolate its gene and determine its 3D structure alone and bound to two separate target enzymes.. Currently, he uses mouse models to demonstrate important roles for these protein kinases in human diseases such as cancer, diabetes/obesity and other components of metabolic syndrome. Dr. Means is a distinguished Professor Emeritus at Duke University Medical Center in Pharmacology and Cancer Biology and is now currently a Professor at Baylor College Medicine, Houston, Texas. In Molecular and Cellular Biology.
John Scott, Ph.D., St Vincent Institute of Medical Research
Dr Scott graduated with a Bachelor of Science (Hons) from the University of Glasgow in 1997, followed by a PhD in Biochemistry from the University of Dundee in 2002 funded by a prestigious Wellcome Trust Prize scholarship. He was recruited to St Vincent’s Institute of Medical Research (SVIMR) in Melbourne in 2006, where he currently leads the Neurometabolism group. Dr Scott is also a Senior Research Academic at the Mary MacKillop Institute of Health Research at ACU and an Honorary Research Fellow of the Florey Institute of Neuroscience and Mental Health. His primary research interest is on understanding the molecular pathways that regulate mood and emotional behavior in response to hormones and metabolites. His is a leading researcher on the control of protein-kinase signalling pathways that regulate whole-body energy metabolism and complex behaviour. Dysregulation of these pathways has strong links with human psychiatric diseases such as bipolar disorder and schizophrenia. His group uses a wide range of techniques including biochemistry, cell biology, protein crystallography, mass spectrometry and genetically modified mouse models to decipher the role of the signalling networks that regulate complex behavior in health and disease.